https://www.selleckchem.com/pr....oducts/3-deazaneplan
This study compares two latest-generation self-expanding transcatheter heart valves (THV), the supra-annular ACURATE neo (Boston Scientific) and the intra-annular Centera THV (Edwards Lifesciences). In this single center observational cohort trial 317 patients treated with the ACURATE neo and 78 patients treated with the Centera TVH were included. The main endpoints were device success and the early safety endpoint at 30 days. Besides higher incidence of diabetes mellitus and higher body mass index in patients treated
Like
Comment
Share
